India-based Glenmark Pharmaceuticals (NSE: GLENMARK) has been granted final approval by the US health regulator to market its generic version of Rythmol SR capsules, the company confirmed on Monday.
Rythmol SR capsules are indicated as an anti-arrhythmic medication, used in the treatment of illnesses whose symptoms include rapid heartbeats.
The US Food and Drug Administration (FDA) granted its approval for Propafenone Hydrochloride extended-release capsules USP, 225 mg, 325 mg and 425 mg.
Rythmol SR is a product of GlaxoSmithKline LLC.
The approval marks the company's 123rd product to gain approval for commercialisation in the US marketplace. It also has 63 Abbreviated New Drug Applications (ANDA) currently pending approval with the FDA.
Egetis receives US notice of allowance for MCT8 deficiency composition patent
Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117